LifeTech Scientific (HKSE:01302) Cash And Cash Equivalents : HK$1,071 Mil (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is LifeTech Scientific Cash And Cash Equivalents?

LifeTech Scientific's quarterly cash and cash equivalents declined from Dec. 2022 (HK$931.11 Mil) to Jun. 2023 (HK$847.84 Mil) but then increased from Jun. 2023 (HK$847.84 Mil) to Dec. 2023 (HK$1,071.15 Mil).

LifeTech Scientific's annual cash and cash equivalents declined from Dec. 2021 (HK$1,370.50 Mil) to Dec. 2022 (HK$931.11 Mil) but then increased from Dec. 2022 (HK$931.11 Mil) to Dec. 2023 (HK$1,071.15 Mil).

LifeTech Scientific Cash And Cash Equivalents Historical Data

The historical data trend for LifeTech Scientific's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LifeTech Scientific Cash And Cash Equivalents Chart

LifeTech Scientific Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

332.74

1,151.87

1,370.50

931.11

1,071.15

LifeTech Scientific Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															1,370.50	1,074.83	931.11	847.84	1,071.15

LifeTech Scientific Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

LifeTech Scientific (HKSE:01302) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

LifeTech Scientific Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of LifeTech Scientific's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

LifeTech Scientific (HKSE:01302) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LifeTech Scientific Corp (HKSE:01302) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

LFTSF:USA 81X:Germany

Address

No. 22, Keji 12th Road South, LifeTech Scientific Building, High-tech Industrial Park, Nanshan District, Shenzhen, CHN, 518063

Website

http://www.lifetechmed.com

LifeTech Scientific Corp develops and manufactures minimally invasive medical devices for cardiovascular and vascular diseases. The firm operates in three areas: Structural heart diseases business; Peripheral vascular diseases business and Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral vascular diseases business segment. Geographically, it derives a majority of revenue from China.

Executives

Xie Yuehui	2201 Interest of corporation controlled by you
Xianjian Advanced Technology Limited	2101 Beneficial owner
Hhlr Advisors, Ltd.	2102 Investment manager
Bank Of Communications Trustee Limited	2301 Trustee
Xie Yuehui	2201 Interest of corporation controlled by you
Hhlr Fund, L.p.	2101 Beneficial owner
Hillhouse Capital Advisors, Ltd.	2102 Investment manager
Gaoling Fund, L.p.	2101 Beneficial owner

LifeTech Scientific (HKSE:01302) Headlines

No Headlines